Skip to main content
Top
Published in: Medical Oncology 5/2014

01-05-2014 | Original Paper

3020insC NOD2/CARD15 polymorphism associated with treatment of colorectal cancer

Authors: Inés Omrane, Amel Mezlini, Olfa Baroudi, Nejla Stambouli, Karim Bougatef, Hager Ayari, Imen Medimegh, Hassen Bouzaienne, Nancy Uhrhammer, Yves-Jean Bignon, Amel Benammar-Elgaaied, Raja Marrakchi

Published in: Medical Oncology | Issue 5/2014

Login to get access

Abstract

Chronic inflammation is closely linked to cancer. The risk of damage by colorectal cancer (CRC) may increase due to autoimmune disease and cryptogenic inflammation. Therefore, genetic factors implicated in the chronic irritation in inflammatory bowel disease such as NOD2/CARD15 may predispose to CRC. In this report, we shed the light on the possible contribution of the NOD2 3020insC variant to CRC risk in a series of 246 Tunisian subjects including 101 patients with CRC and 145 healthy controls. NOD2/CARD15 polymorphism was genotyped by sizing fluorescently labeled PCR products and automated sequencers. We analyzed the association between the molecular features at this gene in relation to tumor and patient characteristics and treatments. Through this qualitative analysis, we found that CRC patients with mutant allele of NOD2/CARD15 were suffering from Crohn’s disease (CD) with canonic presentation. We also observed a positive association between 3020insC polymorphism and surgery and chemotherapy. We suppose that around 3 % of colorectal cases which happen at an age older than 50 years are associated with the canonic form of CD along with the 3020insC mutation and that these patients are in need for chemotherapy.
Literature
1.
go back to reference Bougatef K, Marrakchi R, Ouerhani S, Sassi R, Moussa A, Kourda N, et al. No evidence of the APC D1822V missense variant’s pathogenicity in Tunisian patients with sporadic colorectal cancer. Pathol Biol. 2009;57(3):e67–71.PubMedCrossRef Bougatef K, Marrakchi R, Ouerhani S, Sassi R, Moussa A, Kourda N, et al. No evidence of the APC D1822V missense variant’s pathogenicity in Tunisian patients with sporadic colorectal cancer. Pathol Biol. 2009;57(3):e67–71.PubMedCrossRef
2.
go back to reference Deschoolmeester V, Baay M, Lardon F, Pauwels P, Peeters M. Immune cells in colorectal cancer: prognostic relevance and role of MSI. Cancer Microenviron. 2011;4(3):377–92.PubMedCentralPubMedCrossRef Deschoolmeester V, Baay M, Lardon F, Pauwels P, Peeters M. Immune cells in colorectal cancer: prognostic relevance and role of MSI. Cancer Microenviron. 2011;4(3):377–92.PubMedCentralPubMedCrossRef
3.
go back to reference Mustapha MA, Shahpudin SN, Aziz AA, Ankathil R. Risk modification of colorectal cancer susceptibility by interleukin-8 -251T>A polymorphism in Malaysians. World J Gastroenterol. 2012;18(21):2668–73.PubMedCentralPubMedCrossRef Mustapha MA, Shahpudin SN, Aziz AA, Ankathil R. Risk modification of colorectal cancer susceptibility by interleukin-8 -251T>A polymorphism in Malaysians. World J Gastroenterol. 2012;18(21):2668–73.PubMedCentralPubMedCrossRef
5.
go back to reference Angeletti S, Galluzzo S, Santini D, Ruzzo A, Vincenzi B, Ferraro E, et al. NOD2/CARD15 polymorphisms impair innate immunity and increase susceptibility to gastric cancer in an Italian population. Hum Immunol. 2009;70(9):729–32.PubMedCrossRef Angeletti S, Galluzzo S, Santini D, Ruzzo A, Vincenzi B, Ferraro E, et al. NOD2/CARD15 polymorphisms impair innate immunity and increase susceptibility to gastric cancer in an Italian population. Hum Immunol. 2009;70(9):729–32.PubMedCrossRef
7.
go back to reference Kutikhin AG. Role of NOD1/CARD4 and NOD2/CARD15 gene polymorphisms in cancer etiology. Hum Immunol. 2011;72(10):955–68.PubMedCrossRef Kutikhin AG. Role of NOD1/CARD4 and NOD2/CARD15 gene polymorphisms in cancer etiology. Hum Immunol. 2011;72(10):955–68.PubMedCrossRef
8.
go back to reference Kurzawski G, Suchy J, Kladny J, Grabowska E, Mierzejewski M, Jakubowska A, et al. The NOD2 3020insC mutation and the risk of colorectal cancer. Cancer Res. 2004;64(5):1604–6.PubMedCrossRef Kurzawski G, Suchy J, Kladny J, Grabowska E, Mierzejewski M, Jakubowska A, et al. The NOD2 3020insC mutation and the risk of colorectal cancer. Cancer Res. 2004;64(5):1604–6.PubMedCrossRef
9.
go back to reference Lakatos PL, Lakatos L, Szalay F, Willheim-Polli C, Osterreicher C, Tulassay Z, et al. Toll-like receptor 4 and NOD2/CARD15 mutations in Hungarian patients with Crohn’s disease: phenotype-genotype correlations. World J Gastroenterol. 2005;11(10):1489–95.PubMed Lakatos PL, Lakatos L, Szalay F, Willheim-Polli C, Osterreicher C, Tulassay Z, et al. Toll-like receptor 4 and NOD2/CARD15 mutations in Hungarian patients with Crohn’s disease: phenotype-genotype correlations. World J Gastroenterol. 2005;11(10):1489–95.PubMed
10.
go back to reference Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature. 2001;411(6837):603–6.PubMedCrossRef Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature. 2001;411(6837):603–6.PubMedCrossRef
11.
go back to reference Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature. 2001;411(6837):599–603.PubMedCrossRef Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature. 2001;411(6837):599–603.PubMedCrossRef
12.
go back to reference Lesage S, Zouali H, Cezard JP, Colombel JF, Belaiche J, Almer S, et al. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet. 2002;70(4):845–57.PubMedCentralPubMedCrossRef Lesage S, Zouali H, Cezard JP, Colombel JF, Belaiche J, Almer S, et al. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet. 2002;70(4):845–57.PubMedCentralPubMedCrossRef
13.
go back to reference Papaconstantinou I, Theodoropoulos G, Gazouli M, Panoussopoulos D, Mantzaris GJ, Felekouras E, et al. Association between mutations in the CARD15/NOD2 gene and colorectal cancer in a Greek population. Int J Cancer. 2005;114(3):433–5.PubMedCrossRef Papaconstantinou I, Theodoropoulos G, Gazouli M, Panoussopoulos D, Mantzaris GJ, Felekouras E, et al. Association between mutations in the CARD15/NOD2 gene and colorectal cancer in a Greek population. Int J Cancer. 2005;114(3):433–5.PubMedCrossRef
14.
go back to reference Tian Y, Li Y, Hu Z, Wang D, Sun X, Ren C. Differential effects of NOD2 polymorphisms on colorectal cancer risk: a meta-analysis. Int J Colorectal Dis. 2010;25(2):161–8.PubMedCrossRef Tian Y, Li Y, Hu Z, Wang D, Sun X, Ren C. Differential effects of NOD2 polymorphisms on colorectal cancer risk: a meta-analysis. Int J Colorectal Dis. 2010;25(2):161–8.PubMedCrossRef
15.
go back to reference Lakatos PL, Hitre E, Szalay F, Zinober K, Fuszek P, Lakatos L, et al. Common NOD2/CARD15 variants are not associated with susceptibility or the clinicopathologic characteristics of sporadic colorectal cancer in Hungarian patients. BMC Cancer. 2007;7:54.PubMedCentralPubMedCrossRef Lakatos PL, Hitre E, Szalay F, Zinober K, Fuszek P, Lakatos L, et al. Common NOD2/CARD15 variants are not associated with susceptibility or the clinicopathologic characteristics of sporadic colorectal cancer in Hungarian patients. BMC Cancer. 2007;7:54.PubMedCentralPubMedCrossRef
16.
go back to reference Marrakchi R, Bougatef K, Moussa A, Ouerhani S, Khodjet-el-Khil H, Messai Y, et al. 3020insC insertion in NOD2/CARD15 gene, a prevalent variant associated with anti-Saccharomyces cerevisiae antibodies and ileal location of Crohn’s disease in Tunisian population. Inflamm Res. 2009;58(4):218–23.PubMedCrossRef Marrakchi R, Bougatef K, Moussa A, Ouerhani S, Khodjet-el-Khil H, Messai Y, et al. 3020insC insertion in NOD2/CARD15 gene, a prevalent variant associated with anti-Saccharomyces cerevisiae antibodies and ileal location of Crohn’s disease in Tunisian population. Inflamm Res. 2009;58(4):218–23.PubMedCrossRef
17.
go back to reference Alhopuro P, Ahvenainen T, Mecklin JP, Juhola M, Jarvinen HJ, Karhu A, et al. NOD2 3020insC alone is not sufficient for colorectal cancer predisposition. Cancer Res. 2004;64(20):7245–7.PubMedCrossRef Alhopuro P, Ahvenainen T, Mecklin JP, Juhola M, Jarvinen HJ, Karhu A, et al. NOD2 3020insC alone is not sufficient for colorectal cancer predisposition. Cancer Res. 2004;64(20):7245–7.PubMedCrossRef
18.
go back to reference Mockelmann N, von Schonfels W, Buch S, von Kampen O, Sipos B, Egberts JH, et al. Investigation of innate immunity genes CARD4, CARD8 and CARD15 as germline susceptibility factors for colorectal cancer. BMC gastroenterol. 2009;9:79.PubMedCentralPubMedCrossRef Mockelmann N, von Schonfels W, Buch S, von Kampen O, Sipos B, Egberts JH, et al. Investigation of innate immunity genes CARD4, CARD8 and CARD15 as germline susceptibility factors for colorectal cancer. BMC gastroenterol. 2009;9:79.PubMedCentralPubMedCrossRef
19.
go back to reference Suchy J, Klujszo-Grabowska E, Kladny J, Cybulski C, Wokolorczyk D, Szymanska-Pasternak J, et al. Inflammatory response gene polymorphisms and their relationship with colorectal cancer risk. BMC Cancer. 2008;8:112.PubMedCentralPubMedCrossRef Suchy J, Klujszo-Grabowska E, Kladny J, Cybulski C, Wokolorczyk D, Szymanska-Pasternak J, et al. Inflammatory response gene polymorphisms and their relationship with colorectal cancer risk. BMC Cancer. 2008;8:112.PubMedCentralPubMedCrossRef
20.
go back to reference Roberts RL, Gearry RB, Allington MD, Morrin HR, Robinson BA, Frizelle FA. Caspase recruitment domain-containing protein 15 mutations in patients with colorectal cancer. Cancer Res. 2006;66(5):2532–5.PubMedCrossRef Roberts RL, Gearry RB, Allington MD, Morrin HR, Robinson BA, Frizelle FA. Caspase recruitment domain-containing protein 15 mutations in patients with colorectal cancer. Cancer Res. 2006;66(5):2532–5.PubMedCrossRef
21.
go back to reference Szeliga J, Sondka Z, Jackowski M, Jarkiewicz-Tretyn J, Tretyn A, Malenczyk M. NOD2/CARD15 polymorphism in patients with rectal cancer. Med Sci Monit. 2008;14(9):CR480–4.PubMed Szeliga J, Sondka Z, Jackowski M, Jarkiewicz-Tretyn J, Tretyn A, Malenczyk M. NOD2/CARD15 polymorphism in patients with rectal cancer. Med Sci Monit. 2008;14(9):CR480–4.PubMed
22.
go back to reference Barreiro M, Nunez C, Dominguez-Munoz JE, Lorenzo A, Barreiro F, Potel J, et al. Association of NOD2/CARD15 mutations with previous surgical procedures in Crohn’s disease. Rev Esp Enferm Dig. 2005;97(8):547–53.PubMedCrossRef Barreiro M, Nunez C, Dominguez-Munoz JE, Lorenzo A, Barreiro F, Potel J, et al. Association of NOD2/CARD15 mutations with previous surgical procedures in Crohn’s disease. Rev Esp Enferm Dig. 2005;97(8):547–53.PubMedCrossRef
23.
go back to reference Alvarez-Lobos M, Arostegui JI, Sans M, Tassies D, Plaza S, Delgado S, et al. Crohn’s disease patients carrying Nod2/CARD15 gene variants have an increased and early need for first surgery due to stricturing disease and higher rate of surgical recurrence. Ann Surg. 2005;242(5):693–700.PubMedCentralPubMedCrossRef Alvarez-Lobos M, Arostegui JI, Sans M, Tassies D, Plaza S, Delgado S, et al. Crohn’s disease patients carrying Nod2/CARD15 gene variants have an increased and early need for first surgery due to stricturing disease and higher rate of surgical recurrence. Ann Surg. 2005;242(5):693–700.PubMedCentralPubMedCrossRef
24.
go back to reference Buning C, Genschel J, Buhner S, Kruger S, Kling K, Dignass A, et al. Mutations in the NOD2/CARD15 gene in Crohn’s disease are associated with ileocecal resection and are a risk factor for reoperation. Aliment Pharmacol Ther. 2004;19(10):1073–8.PubMedCrossRef Buning C, Genschel J, Buhner S, Kruger S, Kling K, Dignass A, et al. Mutations in the NOD2/CARD15 gene in Crohn’s disease are associated with ileocecal resection and are a risk factor for reoperation. Aliment Pharmacol Ther. 2004;19(10):1073–8.PubMedCrossRef
25.
go back to reference Laghi L, Costa S, Saibeni S, Bianchi P, Omodei P, Carrara A, et al. Carriage of CARD15 variants and smoking as risk factors for resective surgery in patients with Crohn’s ileal disease. Aliment Pharmacol Ther. 2005;22(6):557–64.PubMedCrossRef Laghi L, Costa S, Saibeni S, Bianchi P, Omodei P, Carrara A, et al. Carriage of CARD15 variants and smoking as risk factors for resective surgery in patients with Crohn’s ileal disease. Aliment Pharmacol Ther. 2005;22(6):557–64.PubMedCrossRef
26.
go back to reference Russell RK, Drummond HE, Nimmo EE, Anderson N, Smith L, Wilson DC, et al. Genotype-phenotype analysis in childhood-onset Crohn’s disease: NOD2/CARD15 variants consistently predict phenotypic characteristics of severe disease. Inflamm Bowel Dis. 2005;11(11):955–64.PubMedCrossRef Russell RK, Drummond HE, Nimmo EE, Anderson N, Smith L, Wilson DC, et al. Genotype-phenotype analysis in childhood-onset Crohn’s disease: NOD2/CARD15 variants consistently predict phenotypic characteristics of severe disease. Inflamm Bowel Dis. 2005;11(11):955–64.PubMedCrossRef
Metadata
Title
3020insC NOD2/CARD15 polymorphism associated with treatment of colorectal cancer
Authors
Inés Omrane
Amel Mezlini
Olfa Baroudi
Nejla Stambouli
Karim Bougatef
Hager Ayari
Imen Medimegh
Hassen Bouzaienne
Nancy Uhrhammer
Yves-Jean Bignon
Amel Benammar-Elgaaied
Raja Marrakchi
Publication date
01-05-2014
Publisher
Springer US
Published in
Medical Oncology / Issue 5/2014
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0954-z

Other articles of this Issue 5/2014

Medical Oncology 5/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.